|
Shilpa Medicare announced that the Companyfs finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana state has undergone a GMP inspection by ANVISA, Brazil starting 21 August 2023. The inspection has concluded successfully on 24 August 2023 without any observations.
The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and non]sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy.
This inspection is the third major regulatory inspection (after Russia and Canada), cleared by this Site in the past two years.
This inspection and subsequent approval will allow the company for the commercial distribution of products in Brazil market and enable approval of new applications for Brazil market.
|